CC-94676 for Metastatic Castration-Resistant Prostate Cancer

Recruiting at 45 trial locations

Overseen By BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

Age: 18+

Sex: Male

Trial Phase: Phase 1

Sponsor: Celgene

Must be taking: Androgen deprivation therapy

Must not be taking: Androgen receptor degraders

Disqualifiers: Concurrent malignancy, Venous thromboembolism, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: 8-12 weeks

250 Participants Needed

Trial Summary

What is the purpose of this trial?

This trial is testing a new drug called CC-94676 to see if it is safe and effective for men with advanced prostate cancer that continues to grow despite hormone-lowering treatments.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research Team

Bristol-Myers Squibb

Principal Investigator

Bristol-Myers Squibb

Eligibility Criteria

Men with advanced prostate cancer that has spread and is resistant to hormone therapy can join this trial. They must have tried at least one other treatment for their condition, be in good physical shape (able to perform daily activities without significant limitations), and not have any other active cancers or recent serious blood clots.

Inclusion Criteria

My prostate cancer diagnosis was confirmed through a lab test.

I am fully active or restricted in physically strenuous activity but can do light work.

My prostate cancer has worsened despite hormone therapy and at least one other treatment.

Exclusion Criteria

I haven't had a serious blood clot in the last 3 months.

I do not have any uncontrolled infections, severe lab abnormalities, or major psychiatric illnesses.

I do not have another cancer needing treatment or any cancer active in the last year.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive CC-94676 to evaluate safety, tolerability, and preliminary efficacy

8-12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

• CC-94676

Trial Overview The study tests the safety and initial effectiveness of three experimental drugs: CC1083610, CC1083611, and CC-94676. These are given to men whose prostate cancer has worsened despite hormone therapy and previous treatments.

Participant Groups

Group I: Administration of CC-94676, CC1083611, and CC1083610 Experimental Treatment 3 Interventions

Who Is Running the Clinical Trial?

Celgene

Lead Sponsor

Trials

649

Recruited

130,000+

Top Products

>- **Revlimid (lenalidomide)**: Multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma treatment. - **Pomalyst (pomalidomide)**: Relapsed/refractory multiple myeloma treatment. - **Otezla (apremilast)**: Psoriatic arthritis treatment. - **Thalomid (thalidomide)**: Erythema nodosum leprosum and multiple myeloma treatment.

Jay Backstrom

Celgene

Chief Medical Officer since 2016

MD

Mark Alles

Celgene

Chief Executive Officer since 2016

Bachelor's degree from Lock Haven University of Pennsylvania